Acute non-lymphocytic leukaemia is a well recognised and increasingly reported complication of treated Hodgkin's disease. The prognosis is generally poor with a disappointing response to chemotherapy. A patient in whom myelodysplastic features appeared after treatment for Hodgkin's disease, to be followed shortly afterwards by acute promyelocytic leukaemia, is reported. Complete remission was achieved and sustained until Hodgkin's disease reappeared three years later when the patient was autografted with a marrow harvested four years earlier. The patient remains in good health with platelet support at the time of writing.
concluded that the risk was greater after chemotherapy alone than after either of the other regimens. The case reported here is intriguing in that some of the well known features of secondary leukaemia after treatment for Hodgkin's disease are found here although the case is otherwise atypical. For example, she typically displayed myelodysplastic features before developing frank leukaemic changes and she had previously had chemotherapy with radiotherapy. However, the leukaemia proved morphologically and cytogenetically to be APML, an unexpected sequel both to myelodysplasia and treated Hodgkin's disease. The leukaemia appeared only a few months after completing treatment for Hodgkin's disease. The median interval from stopping treatment to leukaemia has been calculated at about 34 months'; actuarial analysis suggests that the peak incidence falls between three and nine years after treatment. The short interval in this case raises the possibilities that (a) the leukaemia was part of the natural history of her Hodgkin's disease (cytogenetic studies at the onset of Hodgkin's disease might have been helpful here), and (b) that the appearance of APML following Hodgkin's disease was purely coincidental; or (c) that APML resulted from treatment for Hodgkin's disease, a rarely reported complication. This patient has been remarkably well after her standard treatment for leukaemia and is now in her fourth year of complete remission. The complete remission rate and survival of these patients with secondary ANNL has been disappointingly low,4 5 and prolonged remission is unusual. An approach using marrow transplantation as first line treatment seems more hopeful.67 The response to treatment of secondary leukaemia is generally so poor that patients rarely survive long enough to show signs of relapsed Hodgkin's disease. We have found that a rise in the activity of alkaline phosphatase is a warning sign of relapsed Hodgkin's disease: a substantial increase in lactate dehydrogenase is a frequent finding in acute leukaemia.5 This case conformed to this with a raised alkaline phosphatase and a normal lactate dehydrogenase activity when the Hodgkin's disease relapsed, and the opposite pattern when APML developed.
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